Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: A phase 2 study

American Journal of Tropical Medicine and Hygiene

Volumn 92, Issue 3, 2015, Pages 513-517

  Sundar, Shyam ^a   Singh, Anup ^a   Rai, Madhukar ^a   Chakravarty, Jaya ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; AMPHOTERICIN B;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INDIA; LUNG EDEMA; MALE; NEPHROTOXICITY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TREATMENT DURATION; VISCERAL LEISHMANIASIS; VOMITING; DOSE RESPONSE; DRUG ADMINISTRATION; LEISHMANIASIS, VISCERAL; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AMPHOTERICIN B; CHILD; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84924269340     PISSN: 00029637     EISSN: 14761645     Source Type: Journal    
DOI: 10.4269/ajtmh.14-0259     Document Type: Article

References (28)

1. Searo W, 2005. Regional Strategic Framework for Elimination of Kala-Azar from South-East Asia Region (2005-2015). New Delhi, India: World Health Organization, Regional Office for South-East Asia.
2. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M; Leishmaniasis Control Team WHO, 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7: e35671.
3. World Health Organization, 2010. Control of the Leishmaniasis. Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases. Available at: http://whqlibdoc.who .int/trs/WHO-TRS-949-eng.pdf. Accessed June 29, 2011.
4. Bhattacharya SK, Sur D, Sinha PK, Karbwang J, 2006. Elimination of leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible & operationally achievable. Indian J Med Res 123: 195-196.
5. Thakur CP, Sinha GP, Pandey AK, Barat D, Singh RK, 1994. Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison. Bull World Health Organ 72: 931-936.
6. Thakur CP, Narayan S, 2004. A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol 98: 129-138.
7. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A, 1999. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 93: 319-323.
8. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW, 2004. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 38: 377-383.
9. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, 2010. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504-512.
10. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD, 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 76: 25-32.
11. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R, 2002. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 66: 143-146.
12. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R, 2003. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 37: 800-804.
13. Sundar S, Mehta H, Chhabra A, Singh V, Chauhan V, Desjeux P, Rai M, 2006. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin Infect Dis 42: 608-613.
14. Karande SC, Boby KF, Lahiri KR, Jain MK, Kshirsagar NA, Gokhale PC, Pandya SK, 1995. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal Amphotericin B in a child. Trop Doct 25: 80-81.
15. Mondal S, Bhattacharya P, Rahaman M, Ali N, Goswami RP, 2010. A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy. PLoS Negl Trop Dis 4: e764.
16. Program CTE, 2002. Common Toxicity Criteria. Available at: http://ctep.cancer.gov/reporting/index.html. Accessed October 7, 2009.
17. Chulay JD, Bryceson AD, 1983. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 32: 475-479.
18. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J, 2012. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 55: 543-550.
19. Rahman M, Ahmed BN, Faiz MA, Chowdhury MZ, Islam QT, Sayeedur R, Rahman MR, Hossain M, Bangali AM, Ahmad Z, Islam MN, Mascie-Taylor CG, Berman J, Arana B, 2011. Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. Am J Trop Med Hyg 85: 66-69.
20. Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TP, Beijnen JH, Vanaerschot M, Decuypere S, Dhakal SS, Das ML, Karki P, Singh R, Boelaert M, Dujardin JC, 2013. Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis 56: 1530-1538.
21. Rijal S, Chappuis F, Singh R, Bovier PA, Acharya P, Karki BM, Das ML, Desjeux P, Loutan L, Koirala S, 2003. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 97: 350-354.
22. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW, 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 1104-1107.
23. Mondal DAJ, Hasnain MG, Hossain MS, Ghosh D, Huda MM, Nabi SG, Sundar S, Matlashewski G, Arana D, 2014. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. Lancet Glob Health 2: e51-e57.
24. Bodhe PV, Kotwani RN, Kirodian BG, Pathare AV, Pandey AK, Thakur CP, Kshirsagar NA, 1999. Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 93: 314-318.
25. Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, Barrett J, Anaissie EJ, 2001. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 45: 3487-3496.
26. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW, 2001. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 323: 419-422.
27. Sanath S, Gogtay NJ, Kshirsagar NA, 2005. Post-marketing study to assess the safety, tolerability and effectiveness of FungisomeTM: an Indian liposomal amphotericin B preparation. J Postgrad Med 51: 58-63.
28. Astellas Pharma US, Inc., 2012. Ambisome (Amphotericin B) Liposome for Injection: Prescribing Information. Available at: http://www.astellas.us/docs/ambisome.pd. Accessed August 20, 2013.